Literature DB >> 23296365

Health-related quality of life in children and adolescents with phenylketonuria: unimpaired HRQoL in patients but feared school failure in parents.

Eva Thimm1, Lisa Elena Schmidt, Katrin Heldt, Ute Spiekerkoetter.   

Abstract

Aim of the study was the evaluation of health-related quality of life (HRQoL) and the detection of deviant behavior in early-treated children and adolescents with PKU in comparison with healthy peers. Special focus was laid on the impact of compliance with treatment as defined by the national recommendations on HRQoL. Our investigation in 50 children and adolescents and their parents for the first time demonstrates that despite an overall normal HRQoL in our PKU patient collective, parents are concerned about performance in school especially when phenylalanine concentrations in their children are mainly above the therapeutic range. Adherence to target phenylalanine concentrations ameliorated markedly in patients above 10 years in comparison to younger patients due to relaxed treatment recommendations. Interestingly, this alleged improvement in metabolic control has an impact on the parent assessed but not on the patient assessed appraisal of HRQoL. However, a positive correlation between poor metabolic control and conduct problems was identified by patients' self-assessment. In conclusion, lacking adherence to the strict treatment recommendations in infancy results in significant concern about school success and success in life in parents of PKU patients. With relaxation of dietary phenylalanine restriction at 10 years of age, these concerns diminish.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23296365     DOI: 10.1007/s10545-012-9566-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  26 in total

1.  Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results.

Authors:  U Ravens-Sieberer; M Bullinger
Journal:  Qual Life Res       Date:  1998-07       Impact factor: 4.147

2.  The Strengths and Difficulties Questionnaire: a research note.

Authors:  R Goodman
Journal:  J Child Psychol Psychiatry       Date:  1997-07       Impact factor: 8.982

3.  PKU: high plasma phenylalanine concentrations are associated with increased prevalence of mood swings.

Authors:  Karen Anjema; Margreet van Rijn; Paul H Verkerk; Johannes G M Burgerhof; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Mol Genet Metab       Date:  2011-06-02       Impact factor: 4.797

Review 4.  The neuropsychological profile of early and continuously treated phenylketonuria: orienting, vigilance, and maintenance versus manipulation-functions of working memory.

Authors:  S C J Huijbregts; L M J de Sonneville; F J van Spronsen; R Licht; J A Sergeant
Journal:  Neurosci Biobehav Rev       Date:  2002-10       Impact factor: 8.989

5.  Transition of young adults with phenylketonuria from pediatric to adult care.

Authors:  Ulrike Mütze; Annika Roth; Johannes F W Weigel; Skadi Beblo; Christoph G Baerwald; Peter Bührdel; Wieland Kiess
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

6.  Behaviour and school achievement in patients with early and continuously treated phenylketonuria.

Authors:  B A Stemerdink; A F Kalverboer; J J van der Meere; M W van der Molen; J Huisman; L W de Jong; F M Slijper; P H Verkerk; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

7.  Psychiatric symptoms and disorders in phenylketonuria.

Authors:  V L Brumm; D Bilder; S E Waisbren
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

8.  Psychological and social findings in adolescents with phenylketonuria.

Authors:  J Weglage; B Fünders; B Wilken; D Schubert; E Schmidt; P Burgard; K Ullrich
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

9.  High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial.

Authors:  Amber E ten Hoedt; Leo M J de Sonneville; Baudouin Francois; Nienke M ter Horst; Mirian C H Janssen; M Estela Rubio-Gozalbo; Frits A Wijburg; Carla E M Hollak; Annet M Bosch
Journal:  J Inherit Metab Dis       Date:  2010-12-10       Impact factor: 4.982

10.  Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU).

Authors:  Eva Simon; Martin Schwarz; Judith Roos; Nico Dragano; Max Geraedts; Johannes Siegrist; Gudrun Kamp; Udo Wendel
Journal:  Health Qual Life Outcomes       Date:  2008-03-26       Impact factor: 3.186

View more
  13 in total

Review 1.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 2.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

3.  Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries.

Authors:  Annet M Bosch; Alberto Burlina; Amy Cunningham; Esther Bettiol; Flavie Moreau-Stucker; Ekaterina Koledova; Khadra Benmedjahed; Antoine Regnault
Journal:  Orphanet J Rare Dis       Date:  2015-06-18       Impact factor: 4.123

4.  Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients' and parents' quality of life: the phenylketonuria - quality of life (PKU-QOL) questionnaires.

Authors:  Antoine Regnault; Alberto Burlina; Amy Cunningham; Esther Bettiol; Flavie Moreau-Stucker; Khadra Benmedjahed; Annet M Bosch
Journal:  Orphanet J Rare Dis       Date:  2015-05-10       Impact factor: 4.123

5.  Rare inborn errors of metabolism with movement disorders: a case study to evaluate the impact upon quality of life and adaptive functioning.

Authors:  Hendriekje Eggink; Anouk Kuiper; Kathryn J Peall; Maria Fiorella Contarino; Annet M Bosch; Bart Post; Deborah A Sival; Marina A J Tijssen; Tom J de Koning
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

6.  Quality of Life (QoL) assessment in a cohort of patients with phenylketonuria.

Authors:  Chiara Cazzorla; Luca Cegolon; Alessandro P Burlina; Andrea Celato; Pamela Massa; Laura Giordano; Giulia Polo; Aurora Daniele; Francesco Salvatore; Alberto B Burlina
Journal:  BMC Public Health       Date:  2014-12-04       Impact factor: 3.295

7.  Development of the US English version of the phenylketonuria - quality of life (PKU-QOL) questionnaire.

Authors:  Elaina Jurecki; Amy Cunningham; Vanessa Birardi; Grégory Gagol; Catherine Acquadro
Journal:  Health Qual Life Outcomes       Date:  2017-03-09       Impact factor: 3.186

8.  Depression and anxiety among parents of phenylketonuria children.

Authors:  Mehmet Gunduz; Nur Arslan; Ozlem Unal; Sevim Cakar; Pinar Kuyum; Selda F Bulbul
Journal:  Neurosciences (Riyadh)       Date:  2015-10       Impact factor: 0.906

9.  Quality of life and adherence to treatment in early-treated Brazilian phenylketonuria pediatric patients.

Authors:  E Vieira; H S Maia; C B Monteiro; L M Carvalho; T Tonon; A P Vanz; I V D Schwartz; M G Ribeiro
Journal:  Braz J Med Biol Res       Date:  2017-12-11       Impact factor: 2.590

Review 10.  Patient and observer reported outcome measures to evaluate health-related quality of life in inherited metabolic diseases: a scoping review.

Authors:  Carlota Pascoal; Sandra Brasil; Rita Francisco; Dorinda Marques-da-Silva; Agnes Rafalko; Jaak Jaeken; Paula A Videira; Luísa Barros; Vanessa Dos Reis Ferreira
Journal:  Orphanet J Rare Dis       Date:  2018-11-28       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.